MXCT(MaxCyte, Inc.) · 财务报表

MXCT(MaxCyte, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$33.89M$44.26M$41.29M$38.63M$33.03M
毛利润$30.25M$39.16M$36.55M$31.53M$26.80M
营业利润−$18.19M−$27.36M−$48.30M−$51.20M−$51.90M
净利润−$19.08M−$23.57M−$37.92M−$41.05M−$44.63M
经营现金流−$10.68M−$14.78M−$21.69M−$27.61M−$34.41M
自由现金流−$14.51M−$33.26M−$25.39M−$29.26M−$36.18M
摊薄每股收益$-0.21$-0.23$-0.37$-0.39$-0.42

MaxCyte, Inc. MXCT